TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0160nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0170nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0200nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
Affinity DataKi: 0.0220nMpH: 7.4Assay Description:The binding potencies of sGC compounds to the human recombinant sGC enzyme were determined in a Size Exclusion Chromatography (SEC) competition bindi...More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1/beta-1(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0220nMAssay Description:The binding buffer was composed of 50 mM triethanolamine, pH 7.4, 3 mM MgCl2, 0.025% BSA, 2 mM dithiothreitol (DTT), 300 μM DETA/NO and 400 _...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0220nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0240nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
Affinity DataKi: 0.0250nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1/beta-1(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0260nMAssay Description:The binding buffer was composed of 50 mM triethanolamine, pH 7.4, 3 mM MgCl2, 0.025% BSA, 2 mM dithiothreitol (DTT), 300 μM DETA/NO and 400 _...More data for this Ligand-Target Pair
Affinity DataKi: 0.0260nMpH: 7.4Assay Description:The binding potencies of sGC compounds to the human recombinant sGC enzyme were determined in a Size Exclusion Chromatography (SEC) competition bindi...More data for this Ligand-Target Pair
Affinity DataKi: 0.0270nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
Affinity DataKi: 0.0290nMpH: 7.4Assay Description:The binding potencies of sGC compounds to the human recombinant sGC enzyme were determined in a Size Exclusion Chromatography (SEC) competition bindi...More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1/beta-1(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0290nMAssay Description:The binding buffer was composed of 50 mM triethanolamine, pH 7.4, 3 mM MgCl2, 0.025% BSA, 2 mM dithiothreitol (DTT), 300 μM DETA/NO and 400 _...More data for this Ligand-Target Pair
Affinity DataKi: 0.0300nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0300nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0300nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
Affinity DataKi: 0.0310nMpH: 7.4Assay Description:The binding potencies of sGC compounds to the human recombinant sGC enzyme were determined in a Size Exclusion Chromatography (SEC) competition bindi...More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1/beta-1(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0310nMAssay Description:The binding buffer was composed of 50 mM triethanolamine, pH 7.4, 3 mM MgCl2, 0.025% BSA, 2 mM dithiothreitol (DTT), 300 μM DETA/NO and 400 _...More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1/beta-1(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0310nMAssay Description:The binding buffer was composed of 50 mM triethanolamine, pH 7.4, 3 mM MgCl2, 0.025% BSA, 2 mM dithiothreitol (DTT), 300 μM DETA/NO and 400 _...More data for this Ligand-Target Pair
Affinity DataKi: 0.0310nMpH: 7.4Assay Description:The binding potencies of sGC compounds to the human recombinant sGC enzyme were determined in a Size Exclusion Chromatography (SEC) competition bindi...More data for this Ligand-Target Pair
Affinity DataKi: 0.0310nMpH: 7.4Assay Description:The binding potencies of sGC compounds to the human recombinant sGC enzyme were determined in a Size Exclusion Chromatography (SEC) competition bindi...More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1/beta-1(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0310nMAssay Description:The binding buffer was composed of 50 mM triethanolamine, pH 7.4, 3 mM MgCl2, 0.025% BSA, 2 mM dithiothreitol (DTT), 300 μM DETA/NO and 400 _...More data for this Ligand-Target Pair
Affinity DataKi: 0.0360nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0380nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
Affinity DataKi: 0.0390nMpH: 7.4Assay Description:The binding potencies of sGC compounds to the human recombinant sGC enzyme were determined in a Size Exclusion Chromatography (SEC) competition bindi...More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1/beta-1(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0390nMAssay Description:The binding buffer was composed of 50 mM triethanolamine, pH 7.4, 3 mM MgCl2, 0.025% BSA, 2 mM dithiothreitol (DTT), 300 μM DETA/NO and 400 _...More data for this Ligand-Target Pair
Affinity DataKi: 0.0400nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0400nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0410nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1/beta-1(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0410nMAssay Description:The binding buffer was composed of 50 mM triethanolamine, pH 7.4, 3 mM MgCl2, 0.025% BSA, 2 mM dithiothreitol (DTT), 300 μM DETA/NO and 400 _...More data for this Ligand-Target Pair
Affinity DataKi: 0.0410nMpH: 7.4Assay Description:The binding potencies of sGC compounds to the human recombinant sGC enzyme were determined in a Size Exclusion Chromatography (SEC) competition bindi...More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1/beta-1(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0420nMAssay Description:The binding buffer was composed of 50 mM triethanolamine, pH 7.4, 3 mM MgCl2, 0.025% BSA, 2 mM dithiothreitol (DTT), 300 μM DETA/NO and 400 _...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0420nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
Affinity DataKi: 0.0420nMpH: 7.4Assay Description:The binding potencies of sGC compounds to the human recombinant sGC enzyme were determined in a Size Exclusion Chromatography (SEC) competition bindi...More data for this Ligand-Target Pair
Affinity DataKi: 0.0430nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0440nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0440nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0450nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
Affinity DataKi: 0.0450nMpH: 7.4Assay Description:The binding potencies of sGC compounds to the human recombinant sGC enzyme were determined in a Size Exclusion Chromatography (SEC) competition bindi...More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1/beta-1(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0450nMAssay Description:The binding buffer was composed of 50 mM triethanolamine, pH 7.4, 3 mM MgCl2, 0.025% BSA, 2 mM dithiothreitol (DTT), 300 μM DETA/NO and 400 _...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0460nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1/beta-1(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0470nMAssay Description:The binding buffer was composed of 50 mM triethanolamine, pH 7.4, 3 mM MgCl2, 0.025% BSA, 2 mM dithiothreitol (DTT), 300 μM DETA/NO and 400 _...More data for this Ligand-Target Pair
Affinity DataKi: 0.0470nMpH: 7.4Assay Description:The binding potencies of sGC compounds to the human recombinant sGC enzyme were determined in a Size Exclusion Chromatography (SEC) competition bindi...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0470nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0470nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0480nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0480nMAssay Description:Performed by Lab B. The activity of the compounds in accordance with the present invention as PDE2 inhibitors may be readily determined using a fluor...More data for this Ligand-Target Pair
Affinity DataKi: 0.0480nMpH: 7.4Assay Description:The binding potencies of sGC compounds to the human recombinant sGC enzyme were determined in a Size Exclusion Chromatography (SEC) competition bindi...More data for this Ligand-Target Pair
TargetGuanylate cyclase soluble subunit alpha-1/beta-1(Homo sapiens (Human))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataKi: 0.0480nMAssay Description:The binding buffer was composed of 50 mM triethanolamine, pH 7.4, 3 mM MgCl2, 0.025% BSA, 2 mM dithiothreitol (DTT), 300 μM DETA/NO and 400 _...More data for this Ligand-Target Pair
Affinity DataKi: 0.0490nMpH: 7.4Assay Description:The binding potencies of sGC compounds to the human recombinant sGC enzyme were determined in a Size Exclusion Chromatography (SEC) competition bindi...More data for this Ligand-Target Pair